

# SMML newsletter

## September 2023

**Based on data from July/august 2023**

Monthly updates around multiple myeloma

MMsyndiTrack™

# Objectives

The goal of this newsletter is to give an overview of what is happening around multiple myeloma in terms of medical developments. This is achieved by monitoring news articles, PR releases and scientific reports on one hand. Conversations from HCPs, digital opinion leaders and other influencers attending congresses, offering their opinion on treatments and commenting on new developments on the other hand.

## Who will benefit from this newsletter?

Any professionals interested in keeping up with developments around multiple myeloma:

- Marketers
- Business Analysts
- But also HCPs who want to anticipate the future landscape of MM management

# Introduction on Multiple Myeloma

# What is Multiple Myeloma?



**White blood cells**
(B-lymphocytes)

**70**
**YEARS**

■ 5 year survival rate ~50%


## Read more on Multiple Myeloma:

**MSD MANUAL**
**Professional Version**

→ Professional version in English

→ Professional version in French

**MSD MANUAL**
**Consumer Version**

→ Consumer version in English

→ Consumer version in French

# MM lines of therapy based on to the following definitions




**1st line** Induction prior SCT

For stem cell candidates, the first step to gain a response to reduce the tumor burden before SCT.
Please note that patients who received more than one SCT are considered to be in "1st line prior to stem cell transplant" for the latest SCT procedure planned. For instance, should a patient receive an induction treatment prior to a 2nd SCT, he should be considered as a 1st line transplant patient.

**1st line** Consolidation post SCT

1st line therapy **after** stem cell transplant to **deepen the response** achieved by adding a **short course** of full dose therapy.

**1st line** Maintenance post SCT

1st line therapy **after** stem cell transplant to **sustain the quality of the response** achieved by adding a long course – from several months up to disease progression – of reduced dose therapy.

# Drugs approved by European Medicines Agency (EMA)

| Brand name | Active substance | Manufacturer | Class of therapy | EMA Date of authorisation | Line of treatment | Product Monograph |
|---|---|---|---|---|---|---|
| Revlimid® | lenalidomide | BMS | Immunomodulating agents (IMiDs) | 14/06/2007 | All lines | Click here |
| Thalidomide® / Thalomid® (US) | thalidomide | BMS | Immunomodulating agents (IMiDs) | 16/04/2008 | All lines | Click here |
| Imnovid® / Pomalyst® (US) | pomalidomide | BMS | Immunomodulating agents (IMiDs) | 05/08/2013 | 2L+ (after Revlimid and Velcade) | Click here |
| Pepaxti® / Pepaxto® (US) | melflufen | Oncopeptides AB | Peptide conjugated alkylator | 17/08/2022 | Triple class exposed / 3L+ / 4L+ / 5L+ | Click here |
| Velcade® | bortezomib | Janssen | Proteasome inhibitors (PIs) | 26/04/2004 | 1LSCT / 1LNSCT | Click here |
| Kyprolis® | carfilzomib | Amgen | Proteasome inhibitors (PIs) | 19/11/2015 | 2L+ / 3L+ | Click here |
| Ninlaro® | ixazomib | Takeda | Proteasome inhibitors (PIs) | 21/11/2016 | 2L+ | Click here |
| Farydak® | panobinostat | Novartis + (Secura Bio) | Histone deacetylase inhibitors (HDACis) | 28/08/2015 | 2L+ Relapsed / Refractory | Click here |
| Darzalex® | daratumumab | Janssen | Monoclonal antibody against CD38 (Mabs) | 20/05/2016 | All lines | Click here |
| Empliciti® | elotuzumab | BMS + (AbbVie) | Monoclonal antibody against SLAMF7 (Mabs) | 11/05/2016 | 2L+ / 3L+ | Click here |
| Sarclisa® | isatuximab | Sanofi | Monoclonal antibody against CD38 (Mabs) | 30/05/2020 | 2L+ / 3L+ | Click here |
| Tecvayli® | teclistamab-cqyv | Janssen | Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager | 21/07/2022 | 4L+ (1Pi + 1 IMiDs + 1anti-CD38 Mabs) | Click here |
| Talvey® | talquetamab-tgvs | Janssen | Bispecific antibody targeting GPRC5D receptor | 09/08/2023 (FDA) | 4L+ (1Pi + 1 IMiDs + 1anti-CD38 Mabs) | Click here |
| Elrexfio® | elranatamab-bcmm | Pfizer | Bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager | 14/08/2023 (FDA) | 4L+ (1Pi + 1 IMiDs + 1anti-CD38 Mabs) | Click here |
| Blenrep® / Belamaf® (US) | belantamab mafodotin-blmf | GSK | Antibody-drug conjugates (BCMA) | 25/08/2020 | 2L+ (4L+ after P, IMiD and MAB (L5+ in Italy) | Click here |
| Nexpovio® / Xpovio® (US) | selinexor | Karyopharm Therapeutics | Nuclear export inhibitor (SINE) | 26/03/2021 | Penta-refractory (2xPI + 2xIMiDs + 1 Mab) | Click here |
| Venclyxto® / Venclexta® (US) | venetoclax | AbbVie | B-cell lymphoma 2 (BCL-2) | 04/12/2016 | 2L+ (already used in CLL / AML treatments) | Click here |
| Abecma® | idecabtagene vicleucel | BMS | Cell-based gene therapy (CAR-T) | 18/08/2021 | Triple class exposed / 3L+ / 4L+ / 5L+ | Click here |
| Carvykti® | ciltacabtagene autoleucel | Janssen | Cell-based gene therapy (CAR-T) | 25/05/2022 | L3 / L4+ / L5+ | Click here |
| Aredia® | pamidronate | Novartis | Bisphosphonates for bone disease | 31/10/1991 | Supportive care / Long-term use (5+ years) | Click here |
| Zometa® | zoledronate | Novartis | Bisphosphonates for bone disease | 20/03/2001 | Supportive care / Long-term use (5+ years) | Click here |
| Prolia® + Xgeva® | denosumab | Amgen | Bisphosphonates for bone disease | 26/05/2010 - 13/07/2011 | Supportive care | Prolia® / Xgeva® |
| Mozobil® | plerixafor | Genzyme | Stem cell mobilazor | 30/07/2009 | Supportive care | Click here |

# MM treatment history timeline

- IMiDs
- PIs
- IMS
- Mabs
- HDACi
- SINE
- BCMA
- CAR-T
- BisAbs

**1844** — *"Rhubarb & orange peel, strengthening plaster to the chest, a pound of blood removed & leeches applied for maintenance therapy".*

**1947** — Urethane

**1958** — Melphalan

**1962** — Corticosteroids

**1983** — Autologous transplantation

**1984** — Vincristine + Adriamycin + Dexamethasone

**1999** — thalidomide

**2002** — bortezomib (Velcade®)

**2005** — lenalidomide (Revlimid®)

**2010** — bendamustine (Levact®)

**2012** — carfilzomib (Kyprolis® US)

**2013** — pomalidomide (Imnovid®/Pomalyst®)

**2015** — panabinostat (Farydak®); carfilzomib (Kyprolis® EU)

**2016** — elotuzumab (Empliciti®); daratumumab (Darzalex®); ixazomib (Ninlaro®)

**2020** — belantamab mafodotin (Blenrep® EU Belamaf ® US); selinexor (Nexpovio® EU Xpovio® US); isatuximab (Sarclisa®)

**2021** — idecabtagene vicleucel (Abecma®)

**2022** — ciltacabtagene autoleucel (Carvykti®); teclistamab (Tecvayli®)

**2023** — melflufen (Pepaxti® EU Pepaxto® US); talquetamab (Talvey®); elranatamab (Elrexfio®)

**20??** — marizomib, anetumab ravtansine, venetoclax, oprozomib

# MM studies at APLUSA

**16+** YEARS

**17+** COUNTRIES OVER TIME

UP TO **90** HCPs per wave per country

UP TO **4** WAVES per year

**4,5k** PATIENTS CHARTS per wave

**18k** PATIENTS CHARTS per year (in EU5)

## What's new MMsyndiTrack™

**Launching of a US pilot wave, Why ?**

- Needs from clients for MM US data
- Back data for EU5 for 15 years
- MM US market changing fast
- Different needs in the US market for labs (patients' ethnicity treatments gap as an example)

## *APLUSA's* added value

- Quarterly + month to month data collection (our competitors → only quarterly data)
- Market adaptability: adjusting our questionnaires and updating the list of treatments by including market trends on a monthly basis → **new CAR-Ts + BisAbs**
- Patient's full treatment history
- Deliverables with Power BI DID


July/August 2023

# CONTENTS

# SCOPE

The scope of the analysis is focused on mentions coming **worldwide**.*

There were a total of **65K** mentions from patients recorded during the listening period from **July 1st, 2023**, to **august 31st 2023**.

A majority of mentions came from **News (49%), X (formerly Twitter) (43%), Forums (3%), Tumblr (2%), Reddit (1%), blogs (1%)** and **Instagram (1%)**.

A total of **23K** unique authors were identified.

*myeloma OR multiplemyeloma OR #mmsm OR #Myeloma* OR #Curemyeloma* OR #mmmrd OR #mmsm OR title: ("multiple myeloma" OR myeloma)

***Social media listening period :July/august 2023***
***Scope: worldwide in English***

# Methodology

WEB

*Extraction**

64 984 Mentions

*Filtering*

Also includes:
- patient testimonies
- Post from associations
- financial/market news
- Articles/press release not focusing solely on multiple myeloma

*myeloma OR multiplemyeloma OR #mmsm OR #Myeloma* OR #Curemyeloma* OR #mmmrd OR #mmsm OR title: ("multiple myeloma" OR myeloma)

Phase II and III clinical trials

- Phase II: 1 341 articles
- Phase III: 364 articles

*Exclude:*
- *Financial/market news*
- *Phase I/II clinical trials*
- *Articles non-focusing solely on phase II or III developments*

HCPs

2 350 Mentions

*X (formerly Twitter), Reddit, or forums users self-referencing as healthcare professionals in their bio/flags*

Press releases

3 602 Mentions

*Articles flagged as being press releases*

Market watch

1 073 Mentions

*Articles mentioning drug approval by a national healthcare authority.*

*Can also include non-approvals as well as additional authorizations and recommendations (e.g., medical reimbursements, etc.)*

***Social media listening period :July/august 2023***
***Scope: worldwide in English***

# Drugs in clinical trials (Phase II) monitored during the listening period

| Molecule name | Commercial name | Class | Manufacturer | Trial names + link (ctrl + right click) / line of treatment / Combination being studied |
|---|---|---|---|---|
| lenalidomide | Revlimid® | immunomodulatory drugs (IMiDs) | BMS | GRIFFIN (ND): daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd); FORTE (ND): carfilzomib, lenalidomide, daratumumab, dexamethasone; NCT02969837 (ND): elotuzumab, carfilzomib, lenalidomide, dexamethasone; MASTER (/): dexamethasone, lenalidomide, daratumumab, carfilzomib |
| pomalidomide | Imnovid® / Pomalyst® (US) | immunomodulatory drugs (IMiDs) | BMS | NCT03590652 (RR): daratumumab, ixazomib, pomalidomide, dexamethasone; ELOQUENT-3 (RR): elotuzumab plus pomalidomide, and dexamethasone |
| Bortezomib | Velcade® | Proteasome inhibitors | Takeda | GRIFFIN (ND): daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd); NCT03314181 (RR): Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) |
| carfilzomib | Kyprolis® | Proteasome inhibitor | Amgen | FORTE (ND): carfilzomib, lenalidomide, daratumumab, dexamethasone; NCT02969837 (ND): elotuzumab, carfilzomib, lenalidomide, dexamethasone; MASTER (/): dexamethasone, lenalidomide, daratumumab, carfilzomib<br>Cardamon (/) : cyclophosphamide, dexamethasone, carfilzomib |
| daratumumab | Darzalex® | Monoclonal antibody anti-CD38 | Janssen | GRIFFIN (ND): daratumumab, lenalidomide, bortezomib, and dexamethasone (D-RVd); FORTE (ND): carfilzomib, lenalidomide, daratumumab, dexamethasone; NCT03590652 (RR): daratumumab, ixazomib, pomalidomide, dexamethasone<br>REBUILD (RR): Monotherapy; NCT03314181 (RR): Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib);<br>MASTER (/): dexamethasone, lenalidomide, daratumumab, carfilzomib ; RedirecTT-1 (RR): Teclistamab, talquetamab, daratumumab (Note: Phase I/II currently in phase IB) |
| elotuzumab | Empliciti® | Monoclonal antibody SLAMF7 | BMS/AbbVie | ELOQUENT-3 (RR): elotuzumab plus pomalidomide, and dexamethasone ; NCT02969837 (ND): elotuzumab, carfilzomib, lenalidomide, dexamethasone |
| isatuximab | Sarclisa® | Monoclonal antibody anti-CD38 | Sanofi | NCT05123131 (ND): isatuximab, bortezomib, lenalidomide, dexamethasone; NCT03590652 (RR): daratumumab, ixazomib, pomalidomide, dexamethasone |
| belantamab mafodotin, (GSK2857916) | Blenrep® | Antibody drug–conjugate (ADC) | GSK | DREAMM-2 (RR): Monotherapy |
| cesnicabtagene autoleucel (ARI0002h) | N/A | Humanised CAR T-Cell Therapy Anti-BCMA | N/A | NCT04309981 (RR): Monotherapy |
| ciltacabtagene (cilta cel, JNJ 68284528) | Carvykti® | CAR T-Cell Therapy Anti-BCMA | Janssen | CARTITUDE (RR): Monotherapy; CARTITUDE 2 (RR): Monotherapy |
| equecabtagene Autoleucel | FUCASO® | Humanised CAR T-Cell Therapy Anti-BCMA | IASO Bio + Innovent | FUMANBA-1 (RR): Monotherapy |
| idecabtagene vicleucel (ide cel) | Abecma® | CAR T-Cell Therapy Anti-BCMA | BMS | KarMMa-2 (RR): Monotherapy (one arm with lenalidomide) ; BMTCTN1902 (/): Monotherapy |
| zevorcabtagene autoleucel (zevor cel) | N/A | CAR T-Cell Therapy Anti-BCMA | CARsgen Therapeutics | LUMMICAR-2 (RR): Monotherapy |
| C-CAR088 | N/A | CAR T-Cell Therapy Anti-BCMA | Cellular Biomedicine | NCT05521802 (RR): Monotherapy |
| CART-ddBCMA | N/A | CAR T-Cell Therapy Anti-BCMA | Arcellx, Inc | NCT05396885 (RR): Monotherapy |
| NXC-201 | N/A | CAR T-Cell Therapy Anti-BCMA | Nexcella | NCT04720313 (RR): Monotherapy |
| teclistamab | Tecvayli® | Bispecific Antibody anti-BCMA | Janssen | MajesTEC-1: (RR): Monotherapy; RedirecTT-1 (RR): Teclistamab, talquetamab, daratumumab (Note: Phase I/II currently in phase IB) |
| talquetamab | N/A | Bispecific antibody T-cell redirecting | Janssen | MonumenTAL-1 (RR): Monotherapy: RedirecTT-1 (RR): Teclistamab, talquetamab, daratumumab (Note: Phase I/II currently in phase IB) |
| elranatamab (PF-06863135) | Elrexfio® | Bispecific Antibody anti-BCMA x Anti-CD3 | Pfizer | MagnetisMM-9 (RR): Monotherapy; MagnetisMM-3 (RR): Monotherapy |
| REGN5458 | N/A | Bispecific Antibody anti-BCMA x Anti-CD3 | Regeneron | LINKER-MM1 (RR): Monotherapy (Note: phase I/II) |
| iopofosine | N/A | small-molecule PDC | Cellectar | Clover 1 (/) |
| venetoclax | Venclyxto® | BCL-2 | AbbVie | NCT03314181 (RR): Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) |

# Phase II Relapse/Refractory CAR-T: Equecabtagene Autoleucel Approved in China for Relapsed/Refractory Multiple Myeloma

## Headlines/Hot off the press

**Equecabtagene Autoleucel Approved in China for Relapsed/Refractory Multiple Myeloma**

"China's National Medical Products Administration has approved the new drug application for equecabtagene autoleucel for the treatment of adult patients with relapsed or refractory multiple myeloma who previously received 3 or more lines of therapy, including a proteasome inhibitor and an immunomodulatory drug." Click here to read the full article

## Sponsor

Innovent + IASO BIOTHERAPEUTICS

**FUMANBA-1**

**Ctrl + click to access clinical trial :** NCT05066646

"A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma"

## Molecule

**equecabtagene autoleucel**

*Phase II N= 354 mentions*
*Social media listening period:July 2023*
*Scope: worldwide in English*

# Phase II Relapse/Refractory CAR-T: Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program

## Headlines/Hot off the press

**Arcellx Announces Partial Clinical Hold Lifted on iMMagine-1 Phase 2 Clinical Program and Reports Second Quarter Financial Results**

"Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on the company's CART-ddBCMA investigational new drug for the treatment of patients with relapsed or refractory multiple myeloma (rrMM) and reported financial results for the second quarter ended June 30, 2023. " Click here to read the full article

## Sponsor

ARCELLX

**iMMagine-1**

**Ctrl + click to access clinical trial:**

NCT05396885

"Study of CART-ddBMCA in Relapsed or Refractory Multiple Myeloma (iMMagine-1)"

## Molecule

**CART-ddBCMA**

*Phase II N= 41 mentions*
*Social media listening period: August 2023*
*Scope: worldwide in English*

# Phase II Relapse/Refractory Bispecific therapies: Janssen Receives Positive CHMP Opinions for Novel Bispecific Antibodies talquetamab and teclistamab for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

## Clinical trial mentioned/Sponsor




**MajesTEC-1**
**Ctrl + click to access clinical trial:**
NCT04557098

"A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (MajesTEC-1)"

**MonumenTAL-1**
**Ctrl + click to access clinical trial:**
NCT04634552

"The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3)."

## Headlines/Hot off the press

**"CHMP Recommends Talquetamab Monotherapy for R/R Multiple Myeloma"**

"The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended conditional marketing authorization of talquetamab for use as a single agent in adult patients with relapsed or refractory multiple myeloma who have previously received at least 3 therapies. " Click here to read the full article

**"Teclistamab Snags Positive CHMP Opinion for Relapsed/Refractory Multiple Myeloma"**

"The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended the approval of a Type II variation for teclistamab in the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least 3 prior therapies." Click here to read the full article

## Molecules

**teclistamab**

**talquetamab**


*Phase II N= 57 mentions*
*Social media listening period:July 2023*
*Scope: worldwide in English*

# Phase II Relapse/Refractory Bispecific therapies: European Commission Approves TALVEY® (talquetamab), Janssen's Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

## Clinical trial mentioned/Sponsor




**MonumenTAL-1**
**Ctrl + click to access clinical trial:**
NCT04634552

"The purpose of this study is to evaluate the efficacy of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3)."

**MagnetisMM-3**
**Ctrl + click to access clinical trial :** NCT04649359

"Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb"

## Headlines/Hot off the press

**European Commission Approves TALVEY® (talquetamab), Janssen's Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma**

"Talquetamab, the first bispecific antibody targeting GPRC5D, showed an overall response rate of more than 70 percent with durable responses, including responses achieved by over 60 percent of patients with prior T-cell redirection therapy." Click here to read the full article

**Pfizer's ELREXFIO™ Receives U.S. FDA Accelerated Approval for Relapsed or Refractory Multiple Myeloma**

"Pfizer Inc. today announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval to ELREXFIO™ (elranatamab-bcmm) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. Approval was based on the results of the single-arm Phase 2 MagnetisMM-3 trial, and continued approval for this indication is contingent upon verification of clinical benefit in a confirmatory trial(s). " Click here to read the full article

## Molecules

**talquetamab**

**elranatamab**




*Phase II N= 906 mentions*
*Social media listening period: August 2023*
*Scope: worldwide in English*

# Discussions about the approval of bispecific antibodies talquetamab and elranatamab dominated online mentions from HCPs

## SOV topics of conversations




## SOV molecules







*HCPs conversation N= 2 350 mentions*
*Social media listening period: July/august 2023*
*Scope: worldwide in English*

**Variation of volume compared to previous month*

**emerging*

# Engagement was dominated by Vincent Rajkumar with an educational post being the most retweeted and a professional career announcement being the most liked.

Dr Rajkumar announced his upcoming new duties as chairman, board of directors of the International Myeloma Foundation next year.

Another post from Dr Rajkumar received attention. This post, educational in tone, discussed serum free light chain FLC assay via a thread of 24 tweets in total.

The most replied to post was from Dr Carneiro, an hemato-oncologist from Brazil, where he highlighted the first auto for myeloma reimbursed in the amazon region, deemed an encouraging development for low-income regions in the country. This garnered messages of congratulations from fellow HCPs.

## Most engagement

**Most retweeted, liked and replied to (Ctrl + right click to access tweets)**


*HCPs conversation N= 2 350 mentions*
*Social media listening period: July/august 2023*
*Scope: worldwide in English*

# Media (press releases): volume and articles per peak in July

## Volume of articles overtime




**A**

"Innovent and IASO Bio Announce **the NMPA Approval** of **FUCASO®**, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma" Link

**B**

"Antengene Announces **XPOVIO® Regulatory Approval in Hong Kong** for the Treatment of Relapsed and/or Refractory Multiple Myeloma" Link

**C**

"**NMPA and FDA Approved** the First-in-Human Clinical Trial Applications to Evaluate **LBL-034**, **An Anti-GPRC5D/CD3 Bispecific Antibody** Developed by Leads Biolabs, in Relapsed/Refractory Multiple Myeloma" Link

"Israeli targeted procedure destroys bone marrow cancer cells" Link

**D**

"HaemaLogiX and Peter MacCallum Cancer Centre Announce Myeloma **CAR-T Phase I Clinical Trial** Agreement" Link

"**Immix Biopharma** Subsidiary **Nexcella** Announces **NXC-201** Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting" Link

**E**

"**Moving Mountains** for Multiple Myeloma® **Program to Trek** Through Alaska, July 23-29" Link

"World-Renowned Scientist, **S. Vincent Rajkumar**, MD, **Appointed as Chairman-Elect of the Board of Directors of the International Myeloma Foundation** (IMF)" Link

**E continued**

"**Legend Biotech** shares **gain on** multiple-myeloma **drug sales**" Link

"**New innovation in CAR T cells** paves way for less toxic therapy against multiple myeloma" Link

"Multiple myeloma symptoms are generally nonspecific" Link

**F**

"Myeloma Support Group Leader **Jack Aiello** and Global Finance & Strategy Leader Sanjay Singh **Elected to International Myeloma Foundation Board of Directors**" Link

"Younger Patients With Multiple Myeloma Can Achieve Durable Survival" Link

***Media (press release, excluding financial news) N= 1 840 mentions***
***Social media listening period: July 2023***
***Scope: worldwide in English***

# Media (press releases): volume and articles per peak in august

## Volume of articles overtime




**A** "**U.S. FDA Approves TALVEY™ (talquetamab-tgvs),** a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma" Link

**B** **Accelerated Approval** for **Elranatamab-bcmm** in Patients With Relapsed or Refractory Multiple Myeloma Link

***Media (press release, excluding financial news) N= 1 762 mentions***
***Social media listening period: August 2023***
***Scope: worldwide in English***

# Articles per theme

## Bispecifics

- "**NMPA and FDA Approved** the First-in-Human Clinical Trial Applications to Evaluate **LBL-034**, **An Anti-GPRC5D/CD3 Bispecific Antibody** Developed by Leads Biolabs, in Relapsed/Refractory Multiple Myeloma" Link
- "**U.S. FDA Approves TALVEY™ (talquetamab-tgvs),** a First-in-Class Bispecific Therapy for the Treatment of Patients with Heavily Pretreated Multiple Myeloma" Link
- **Accelerated Approval** for **Elranatamab-bcmm** in Patients With Relapsed or Refractory Multiple Myeloma Link

## CAR T-cell therapy

- "Innovent and IASO Bio Announce **the NMPA Approval** of **FUCASO®**, the First Fully-human BCMA CAR-T Therapy, for the Treatment of Relapsed or Refractory Multiple Myeloma" Link
- **"HaemaLogiX** and Peter MacCallum Cancer Centre Announce Myeloma **CAR-T Phase I Clinical Trial Agreement"** Link
- "**Immix Biopharma** Subsidiary **Nexcella** Announces **NXC-201** Multiple Myeloma Clinical Data Abstract Accepted for Presentation at the 20th International Myeloma Society Annual Meeting" Link

## CAR T-cell therapy

- "**Legend Biotech** shares **gain on** multiple-myeloma **drug sales**" Link
- "**New innovation in CAR T cells** paves way for less toxic therapy against multiple myeloma" Link

## Myeloma foundation

- "World-Renowned Scientist, **S. Vincent Rajkumar**, MD, **Appointed as Chairman-Elect of the Board of Directors of the International Myeloma Foundation** (IMF)" Link
- "Myeloma Support Group Leader **Jack Aiello** and Global Finance & Strategy Leader Sanjay Singh **Elected to International Myeloma Foundation Board of Directors**" Link

## Nuclear export inhibitor (SINE)

"Antengene Announces **XPOVIO® Regulatory Approval in Hong Kong** for the Treatment of Relapsed and/or Refractory Multiple Myeloma" Link

## Raising awareness

"**Moving Mountains** for Multiple Myeloma® **Program to Trek** Through Alaska, July 23-29" Link

## Patient life

- "Multiple myeloma symptoms are generally nonspecific" Link
- "Younger Patients With Multiple Myeloma Can Achieve Durable Survival" Link

## RNA-based targeted lipid nanoparticles

"Israeli targeted procedure destroys bone marrow cancer cells" Link

*Media (press release, excluding financial news) N= 3 602 mentions*
*Social media listening period: July/August 2023*
*Scope: worldwide in English*

# Drug Market Watch

## July/August 2023

NICE
National Institute for Health and Care Excellence

> Disappointment as **NICE turns down** next-generation drug (**Blenrep**) Link

Health Canada

> Health Canada Authorizes **TECVAYLI** (teclistamab injection), a First-in-Class Bispecific Antibody for the Treatment of Patients with **Relapsed or Refractory Multiple Myeloma** Link



国家药品监督管理局
National Medical Products Administration

> **Equecabtagene Autoleucel** Approved in **China** for Relapsed/Refractory Multiple Myeloma Link

Department of Health
The Government of the Hong Kong Special Administrative Region

> Antengene Announces **XPOVIO®** Regulatory Approval in **Hong Kong** for the Treatment of Relapsed and/or Refractory Multiple Myeloma Link

FDA

> FDA grants **orphan drug status** for Ichnos' multiple myeloma antibody Link

> U.S. FDA **Approves** TALVEY™ (**talquetamab-tgvs**), a First-in-Class Bispecific Therapy for the Treatment of Patients with **Heavily Pretreated Multiple Myeloma** Link

> Pfizer's **ELREXFIO™** Receives U.S. FDA Accelerated Approval for **Relapsed or Refractory Multiple Myeloma** Link

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

> **Janssen Receives Positive CHMP Opinions** for Novel Bispecific Antibodies TALVEY (**talquetamab**) and TECVAYLI (**teclistamab**) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
> Link

> European Commission Approves **TALVEY®** (**talquetamab**), Janssen's Novel Bispecific Therapy for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma Link